Zobrazeno 1 - 10
of 236
pro vyhledávání: '"Clemens Martin Wendtner"'
Autor:
Nadine Kutsch, Sandra Robrecht, Anna Fink, Elisabeth Lange, Rudolf Weide, Michael G. Kiehl, Martin Sökler, Rudolf Schlag, Ursula Vehling‐Kaiser, Georg Köchling, Christoph Plöger, Michael Gregor, Torben Plesner, Michael R. Clausen, Ilske Oschlies, Matthias Ritgen, Marco Herling, Kirsten Fischer, Hartmut Döhner, Clemens‐Martin Wendtner, Karl‐Anton Kreuzer, Stephan Stilgenbauer, Michael Hallek, Sebastian Böttcher, Wolfram Klapper, Barbara Eichhorst
Publikováno v:
HemaSphere, Vol 8, Iss 7, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/44d232eb23a94fed9624ca9d7e5fa99f
Autor:
Nadine Kutsch, Christian Pallasch, Thomas Decker, Holger Hebart, Kai Uwe Chow, Ullrich Graeven, Jens Kisro, Alexander Kroeber, Eugen Tausch, Kirsten Fischer, Anna-Maria Fink, Clemens-Martin Wendtner, Matthias Ritgen, Stephan Stilgenbauer, Danjie Zhang, Biao Li, Juliane M. Jürgensmeier, Nishanthan Rajakumaraswamy, Pankaj Bhargava, Michael Hallek, Barbara Eichhorst
Publikováno v:
HemaSphere, Vol 6, Iss 6, p e729 (2022)
Externí odkaz:
https://doaj.org/article/dcb0aae89c3a4826bbe95658972ef6d0
Autor:
Hye Kyung Lee, Manuela A. Hoechstetter, Maike Buchner, Trang Thu Pham, Jin Won Huh, Katharina Müller, Sabine Zange, Heiner von Buttlar, Philipp Girl, Roman Wölfel, Lisa Brandmeier, Lisa Pfeuffer, Priscilla A. Furth, Clemens-Martin Wendtner, Lothar Hennighausen
Publikováno v:
Blood Advances. 7:2214-2227
Patients with chronic lymphocytic leukemia (CLL) treated with B-cell pathway inhibitors and anti-CD20 antibodies exhibit low humoral response rates following SARS-CoV-2 vaccination. To investigate this observation, a prospective single-institution st
Autor:
Simon Rule, Wolney Gois Barreto, Javier Briones, Angelo M. Carella, Olivier Casasnovas, Chris Pocock, Clemens-Martin Wendtner, Francesco Zaja, Susan Robson, Lachlan MacGregor, Roger R. Tschopp, Sonja Nick, Martin Dreyling
Publikováno v:
Haematologica, Vol 107, Iss 2 (2021)
Rituximab plus chemotherapy induction followed by rituximab maintenance for up to 2 years confers a long-term benefit in terms of progression-free survival in patients with indolent non-Hodgkin lymphoma. It is not known whether further prolonged main
Externí odkaz:
https://doaj.org/article/06a449fe006b470f83af9d587d57d78f
Autor:
Thomas Luft, Clemens-Martin Wendtner, Florentina Kosely, Aleksandar Radujkovic, Axel Benner, Felix Korell, Lars Kihm, Matthias F. Bauer, Peter Dreger, Uta Merle
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
BackgroundThe coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has evoked a pandemic that challenges public health-care systems worldwide. Endothelial cell dysfunction plays a key role
Externí odkaz:
https://doaj.org/article/4b85aab98f1f4f79b81dd0b27c5e6c45
Autor:
Thomas Wimmer, Raphael Mattes, Hans-Joachim Stemmler, Fabian Hauck, Hendrik Schulze-Koops, Stephanie-Susanne Stecher, Michael Starck, Clemens-Martin Wendtner, Peter Bojko, Marcus Hentrich, Katharina E. Nickel, Katharina S. Götze, Florian Bassermann, Michael von Bergwelt-Baildon, Karsten Spiekermann
Publikováno v:
Blood Advances. 7:832-844
Hemophagocytic lymphohistiocytosis (HLH) is a rare but often fatal hyperinflammatory syndrome caused by an inborn or acquired error of immunity. In adults, the underlying immunodeficiency generally arises alongside severe infections, malignancies, au
Autor:
Tatjana Schwarz, Kirsten Heiss, Yuvaraj Mahendran, Fiordiligie Casilag, Florian Kurth, Leif E. Sander, Clemens-Martin Wendtner, Manuela A. Hoechstetter, Marcel A. Müller, Renate Sekul, Christian Drosten, Volker Stadler, Victor M. Corman
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
The WHO declared the COVID-19 outbreak a public health emergency of international concern. The causative agent of this acute respiratory disease is a newly emerged coronavirus, named SARS-CoV-2, which originated in China in late 2019. Exposure to SAR
Externí odkaz:
https://doaj.org/article/3703b510281d4a20ae1f241d4edb6659
Autor:
Nadine, Kutsch, Emily Eva, Holmes, Sandra, Robrecht, Gudrun, Schüler, Ursula, Vehling-Kaiser, Thomas, Decker, Sigrun, Müller-Hagen, Karin, Heinisch, Sebastian, Böttcher, Matthias, Ritgen, Karl-Anton, Kreuzer, Stephan, Stilgenbauer, Anna Maria, Fink, Kirsten, Fischer, Barbara, Eichhorst, Michael, Hallek, Clemens-Martin, Wendtner
Publikováno v:
Leukemia & Lymphoma. 64:478-482
Autor:
Stephan Stilgenbauer, Franck Morschhauser, Clemens-Martin Wendtner, Guillaume Cartron, Michael Hallek, Barbara Eichhorst, Mark F. Kozloff, Thomas Giever, Gerard Lozanski, Yanwen Jiang, Huang Huang, Daniela Soriano Pignataro, William Schary, Kathryn Humphrey, Mehrdad Mobasher, Gilles Salles
Publikováno v:
Haematologica, Vol 106, Iss 11 (2020)
Venetoclax (Ven), an orally administered, potent BCL-2 inhibitor, has demonstrated efficacy in chronic lymphocytic leukemia (CLL) in combination with rituximab (R) or obinutuzumab (G). Our aim was to investigate the addition of bendamustine (B) to th
Externí odkaz:
https://doaj.org/article/1a1f8f69ec2f440c9474f9d204dd342e
Autor:
Paula Cramer, Julia v. Tresckow, Sandra Robrecht, Jasmin Bahlo, Moritz Fürstenau, Petra Langerbeins, Natali Pflug, Othman Al-Sawaf, Werner J. Heinz, Ursula Vehling-Kaiser, Jan Dürig, Eugen Tausch, Manfred Hensel, Stephanie Sasse, Anna-Maria Fink, Kirsten Fischer, Karl-Anton Kreuzer, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Clemens-Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Publikováno v:
Haematologica, Vol 106, Iss 2 (2020)
The introduction of targeted agents has revolutionized the treatment of chronic lymphocytic leukemia but only few patients achieve complete remissions and minimal residual disease negativity with ibrutinib monotherapy. This multicenter, investigator-
Externí odkaz:
https://doaj.org/article/2ca066e2adef4fddaa1e0e1cd1ae9f54